| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2122033 | European Journal of Cancer | 2014 | 10 Pages |
Abstract
This review describes the molecular mechanisms by which tumour cells may adapt to and evade HER-2 inhibition by HER-2-targeted therapies and discusses strategies to prevent and overcome resistance to trastuzumab and lapatinib. These strategies may include the establishment of predictive markers, exploration of combination therapies and modulation of nodal targets.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jean-Christophe Thery, Jean-Philippe Spano, David Azria, Eric Raymond, Frédérique Penault Llorca,